Napoleone FerraraDistinguished Professor UC San Diego
Anderson ClarkDirector of in vivo Pharmacology EMD Serono
Frank GibbonsPrincipal Scientist AstraZeneca
George NaumovSenior Research Biologist Merck
Tumor Models gives you the tools to develop and utilize the very best preclinical oncology models.
This is a meeting for drug developers who are looking for answers to the difficulties faced with preclinical oncology models that are currently being used to test new cancer drugs. This is a forum to learn what you really need to know about the models pharma are using that are superior in predicting efficacy and mimicking tumor activity in patients. It’s also the best way to identify what preclinical questions need to be answered and make the best possible translational decisions. Decisions that will lead to more effective drug performance in the clinic.
Tumor Models will arm you with everything you need to know to ensure that your tumor models are as predictive of clinical outcome as possible. Whether you’re looking to build more humanized models to ensure more predictive results, or looking to interpret the data from existing technology to make better decisions, this agenda has been designed to cure your headaches.
Never before has such a breadth of drug developers and world renowned academics been brought together to address the issues associated with Tumor Models. Listen to Napoleone Ferrara and Terri Van Dyke as they share their world respected views on how to address the current rate of attrition using tumor models. 16 distinct drug developers will be sharing their secrets to the models they use and the data generated for translational decision making. Learn from them. Ask them questions. Expand your list of contacts.
Attendees will leave armed with a list of practical ideas to optimize their current tumor models. Meet and network with cancer researchers, academics and drug developers to ensure maximum quality of discussions and add valuable contacts to your network.
A: Modelling and Simulation for Effective Translation of PK/PD, Efficacy and Toxicity
run by Jay Mettetal, Senior Scientist,
B: Optimizing Your Current Tumor Imaging Capabilities to more Accurately Visualize the Impact of a Drug on a Tumor in Your Preclinical Model
run by Dai Fukumura,
Massachusetts General Hospital
C: Exploring Patient-Derived Tumor Xenografts to Enhance Data Sets and Improve Efficacy Predictions
by John Tentler, Associate Professor,
University of Colarado
"I got much more out of this conference than from the recent AACR conference" AstraZeneca
"Very valuable and useful information. One of the best meetings I've attended" Millennium
"It exceeded my expectations. The talks were high quality and the interaction amongst participants was excellent" Genentech
"Excellent presentations covering a good spread of approaches and technologies." MedImmune